Overall verdict
Buy
7.8/10
1-year performance
-4.44%
Score breakdown
Down 4.4% over 1 year, 62% of the 52-week range.
Strongest: Financial strength 10.0/10. Weakest: Growth 7.2/10.
13 analysts.
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring ;
NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry ; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings ; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance ;
and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion ; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes ;
MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors ; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Sector
Health Care
Industry
Health Care Equipment and Supplies
Primary listing
Nyse
United States
CEO
Michael Farrell
Founded
1989
Employees
11 370
Revenue / employee
497 225 USD
Next earnings
January 21, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC3.14%
- Bank of New York Mellon Corp2.65%
- FMR LLC0.18%
- Rest of the register94.03%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
277.67 USD
52-week low
180.26 USD
1-year performance
-4.44%
Declining
Year-to-date performance
-0.37%
Declining
Drawdown
-13.25%
Mild pullback
Position in the 52-week range
62% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did better than the world ETF once risk is accounted for.
$10,000 placed at the end of December 2000 are worth today
| ResMed | $279,836 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 1.9 times as much as the world ETF.
- Worst fall:-54Â % between September 2021 and October 2023. $10,000 placed at the top fell to $4,601. The world ETF, at worst: -53Â %. Back to its high in 22 months.
ResMed earned 4 times as much as the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- ResMed: $279,836
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Based on past performance. This is not a recommendation.
Range: 235.08 USD - 258.89 USD (2 methods agree)
The price implies growth of 5.67% per year; the company grows at 25.00%.
Gross margin 60.5%, net margin 27.8%, ROIC 24.4%, ROE 26.4%.
Net margin
27.79%
Exceptional
Sector 9.11%|S&P 13.40%
Gross margin
60.49%
Fair
Return on equity (ROE)
26.40%
Exceptional
Sector 7.42%|S&P 17.06%
Return on invested capital (ROIC)
24.43%
Exceptional
Free cash flow margin (FCF)
28.06%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.01x
Fair
Margin stability
4.6 pts
Steady
Revenue to net income
Growth
7.2/10Revenue up 5.9% over 1 year, 12.1% a year over 5, EPS 26.3% a year over 5.
Revenue (trailing 12 months)
5.7Md USD
Revenue growth (1y)
5.93%
Moderate
Revenue growth (3y)
33.87%
Solid
EPS growth (1y)
22.97%
Hyper-growth
EPS CAGR (5y)
26.34%
Exceptional
EPS revisions (3 months)
1.57%
Revised up
Valuation
7.2/10P/E 21.9x, forward P/E 20.2x, EV/EBITDA 15.9x, PEG 0.83. The multiple sits in the 10th percentile of its own 5-year history.
P/E (TTM)
21.9x
Fair
Sector 29.3x|S&P 23.6x
Forward P/E
20.2x
Fair
EV / EBITDA
15.9x
Fair
Sector 14.2x|S&P 15.5x
PEG
0.83
Growth unpriced
Sector 1.25|S&P 0.91
Fair value (reverse DCF)
243.24 USD
Fairly priced
P/E vs its own 5-year history
among the 10% lowest valuations
Far cheaper than usual
Market cap
33.9Md USD
Financial strength
10.0/10Cash covers 168.6% of the debt, net debt/EBITDA -0.3x.
Net debt / EBITDA
-0.3x
Very solid
Gearing (net debt / equity)
-7.04%
Net cash
Cash
1.0Md USD
Cash / market cap
3.04%
Tight
Cash / total debt
168.56%
Net cash
Interest coverage
81.1x
Very solid
Net debt
-419M USD
Equity
5.9Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 234.11 USD
- MM20241.79
- MM50231.65
- MM200224.14
- RSI 1447.2
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-0.45%
200-day average slope, 3 months
-2.59%
50-day average slope, 1 month
+2.65%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.78 % per day
Volatility change
+38.29%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2027 | 11.95 (16) | 12.14 (21) | 5 830 (29) | 2 249 (20) | 1 690 (18) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 10, 2026.
Same sub-industry: 187 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RMD | 7.8 | 8.2 | 33.9Md USD | 21.9x | 27.8 % | 5.9 % | 24.4 % | -0.3x | 4.7 % | -4.4 % | ||
| 2 | SYK | 6.5 | 6.1 | 121Md USD | 34.0x | 13.8 % | 7.6 % | 9.7 % | 1.7x | 3.8 % | -10.5 % | ||
| 3 | IDXX | 6.3 | 5.7 | 55.4Md USD | 47.4x | 25.4 % | 9.9 % | 54.9 % | 0.5x | 2.3 % | -1.2 % | ||
| 4 | ISRG | 6.2 | 5.5 | 156Md USD | 54.4x | 25.5 % | 21.7 % | 18.0 % | -1.6x | 2.3 % | -21.8 % | ||
| 5 | MDT | 6.2 | 6.7 | 130Md USD | 25.0x | 13.9 % | 13.7 % | 7.0 % | 2.0x | 4.7 % | 9.3 % | ||
| 6 | ABT | 6.0 | 5.2 | 189Md USD | 40.3x | 9.8 % | 14.5 % | 6.6 % | 0.5x | 3.6 % | -13.7 % | ||
| 7 | EW | 5.9 | 5.1 | 60.8Md USD | 61.6x | 14.9 % | 10.5 % | 8.9 % | -2.0x | 2.3 % | 25.3 % | ||
| 8 | BSX | 5.6 | 6.4 | 65.4Md USD | 19.1x | 16.6 % | 1.4 % | 9.8 % | 1.8x | 5.1 % | -55.5 % | ||
| 9 | BDX | 5.5 | 5.3 | 58.4Md USD | 51.8x | 7.4 % | -10.5 % | 3.6 % | 2.9x | 4.6 % | 49.4 % |
